Bone Marrow Transplantation Clinical Trial
Official title:
A Pilot Study to Determine the Feasibility of Fecal MicrobiotaTransplantation (FMT) in Hematopoietic Stem Cell Transplantation (HSCT) Recipients
Verified date | December 2017 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is studying an intervention called fecal microbiota transplantation (FMT). Patients who are scheduled to undergo Hematopoietic Stem Cell Transplantation are invited to take part in this clinical trial to undergo empiric FMT soon after hematopoietic engraftment. The primary endpoint will be to assess the feasibility of FMT in this population and to assess safety.
Status | Completed |
Enrollment | 18 |
Est. completion date | December 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Men or women = 18 and = 65 years old - Patients designated to undergo myeloablative or intermediate intensity allogeneic peripheral blood or bone marrow hematopoietic cell transplantation. Consent will be obtained prior to admission for HSCT. Patients receiving any donor source of stem cells are eligible. Eligible conditioning regimens are those defined as myeloablative by Consensus Criteria (Bacigalupo 2009) as well as the combination of fludarabine with melphalan (100-140 mg/mg2) - Any Graft-vs-Host disease (GVHD) prophylaxis regimen is allowed. - Eastern Cooperative Oncology Group (ECOG) performance status = 2 (Karnofsky = 60%, see Appendix A) - Patients with adequate physical function as measured by - Cardiac: Left ventricular ejection fraction at rest must be = 40%, or shortening fraction >25%. - Hepatic: - Bilirubin = 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis - Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Alkaline Phosphatase < 5 x Upper Limit of Institutional Normal Range (ULN). - Renal: Serum creatinine within normal range, or if serum creatinine is outside normal range, then renal function (measured or estimated creatinine clearance or GFR) = 40millileters/min/1.73m2. - Pulmonary: Diffusing lung capacity for carbon monoxide (DLCO) (corrected for hemoglobin), Forced expiratory volume in 1 second (FEV1) and Forced vital capacity (FVC) = 50% predicted. - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT. - Ability to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool. - Ability to swallow oral medications. Exclusion Criteria: - Prior allogeneic hematopoietic stem cell transplantation. (Patients may have received a prior autologous hematopoietic stem cell transplant.) - Participants who are receiving any other investigational agents. - Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. - Patients with history of primary idiopathic myelofibrosis or any severe marrow fibrosis. - Planned use of prophylactic donor lymphocyte infusion (DLI) therapy. - Delayed gastric emptying syndrome - Known chronic aspiration - Patients with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs) - Pregnant and breast-feeding women are ineligible because they are not eligible for hematopoietic stem cell transplantation. - HIV-positive participants are ineligible. - Participants who are unable to swallow pills. - Participants with end-stage liver disease (cirrhosis) - Participants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis) - Participants with inflammatory bowel disease (e.g., ulcerative colitis, Crohn's) |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts general Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility measured by number of participants able to ingest 15 FMT capsules over a 2-day period | Number of participants able to ingest 15 FMT capsules over a 2 day period. | 2 days | |
Secondary | Progression Free Survival | 2 years | ||
Secondary | Overall Survival | 2 years | ||
Secondary | Cumulative Incidence Of aGVHD | 2 years | ||
Secondary | Non-Relapse Mortality Rate | 2 years | ||
Secondary | Number of participants with treatment-related adverse events | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
Completed |
NCT02212236 -
Psychological Intervention for Distress During HSCT
|
Phase 2 | |
Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
Completed |
NCT01466335 -
An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers
|
Phase 1 | |
Withdrawn |
NCT02682953 -
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
|
Phase 2 | |
Completed |
NCT00775632 -
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
|
Phase 2 | |
Completed |
NCT00048256 -
Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates
|
N/A | |
Completed |
NCT00004994 -
Comparison of Quality of Life in Patients Undergoing More Intensive Versus Less Intensive Chemotherapy and Radiation Preceding a Bone Marrow Transplant
|
N/A | |
Completed |
NCT04039100 -
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
|
N/A | |
Completed |
NCT04535570 -
Evolution of the Energy Expenditure During Hematopoietic Stem Cell Transplantation
|
||
Recruiting |
NCT06118853 -
Impact of Yoga and Gentle Massage Practices on Symptom Management in Patients Undergoing HSCT
|
N/A | |
Active, not recruiting |
NCT01016093 -
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01015183 -
Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
|
Phase 2/Phase 3 | |
Completed |
NCT00843180 -
Massage for Pediatric Oncology
|
N/A | |
Completed |
NCT00000591 -
T-Cell Depletion in Unrelated Donor Marrow Transplantation
|
Phase 3 | |
Completed |
NCT04474730 -
Physical Activity Monitoring Among BMT Patients
|
N/A | |
Active, not recruiting |
NCT02319226 -
Toward Immune Biomarkers for Tolerance and GvHD in Humans
|
||
Recruiting |
NCT00673348 -
Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations
|
N/A | |
Completed |
NCT00005556 -
Retention of Bone Marrow Donors in a National Registry
|
N/A | |
Completed |
NCT05391347 -
Effects of Orange Oil Aromatherapy on the Pain and Anxiety
|
N/A |